The WNK1-ERK5 route plays a pathophysiological role in ovarian cancer and limits therapeutic efficacy of trametinib.
Adrián Sánchez-FdezSofía Matilla-AlmazánJuan Carlos MonteroSofía Del CarmenMar AbadSara García-AlonsoSomshuvra BhattacharyaKristin CalarPilar de la PuenteAlberto OcañaAtanasio PandiellaAzucena Esparís-OgandoPublished in: Clinical and translational medicine (2023)
The present study uncovers the participation of WNK1-MEK5-ERK5 axis in ovarian cancer pathophysiology, opening the possibility of acting on this pathway with therapeutic purposes. Another important finding of the present study was the activation of that signalling axis by trametinib, bypassing the anti-tumoural efficacy of this drug. That fact should be considered in the context of the use of trametinib in ovarian cancer.